Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'Harmonious' meeting between Merz, Lula despite Belém controversy - 2Whale stranded off Germany for days found stuck again
- 3Hundreds of kilos of protected plant seized by Israel Nature and Parks Authority in Golan
- 4A Past filled with Old Civilizations: The World's Most established Societies
- 5Activists guilty over Palestine protest breach
- Changes to CDC website spark debate over autism and vaccine misinformation
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- In blow to Lula, Brazil Congress revives controversial environmental bill
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- 'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
